AnCan and The Marsh (well renown, long-established theater company with a large following in the Bay Area and venues in San Francisco and Oakland) collaborateevery 4th Wednesday of the month for Solo Arts Heal.
You’ll love our March guest, Beth Horner!Noted for her vivacious stage presence, comic sensibility and warm, energetic style, Storyteller Beth possesses a repertoire of stories that has been called “heartfelt, articulate and truthful.”
A National Storytelling Network Circle of Excellence Oracle Award recipient, Beth is a 40-year internationally touring spoken word artist who is sought after as a Storyteller, teaching artist, consultant and narrative coach.
She has performed multiple times at the National Storytelling Festival, for NASA, on Live From National Geographic, for the International Art of Storytelling Festival, the Starlight Educational Foundation of Taiwan, and for Lyrics & Lore: A Weekend with Songwriters & Storytellers at Dollywood’s DreamMore Resort.
She is a former Board Member of the National Storytelling Association, conducted a series of workshops for NASA Engineers and Astrobiologists in California and Washington, D.C., and served as narrative consultant for NASA/Johnson Space Center’s Story Mining project for which she collected the stories of the scientists behind the Apollo Space Missions.
Ron (Beth Horner’s partner) driving Corvette
Most recently, Beth presented Storytelling: A Heart to Heart Connection for the American Parkinson Disease Association’s 2024 Annual Conference. Beth’s love of all kinds of stories – traditional, literary, family, musical, historical and hysterical – makes her a joyous emissary into the world of story.
Beth will regale us with the slightly terrifying hundred mile an hour racetrack experience that sparked her revelation as a care partner (pictured): that amidst the cacophony of financial worries, doctor’s appointments, overwhelming research, deluge of therapies, legal hurdles and all other care partner jobs, it is the care of the spirit that must soar above all else.
Patient Highlights from the 2024 ASCO GU conference
In a 75-minute “pre-game” before the 2/27/2024 meeting of the high-risk/recurrent/advanced prostate cancer group, moderators John, Rick, Ben, and Len discussed highlights from the just-concluded ASCO GU conference, a major meeting for genitourinary cancer specialists. They selected from hundreds of papers on prostate cancer presented in sessions and posters. We closed with a 30-minute audience Q&A.
What we covered:
Abi boosts olaparaib for BRCA
After triplet therapy, what next?
Less treatment, same cancer-fighting power
Trial of a neuroendocrine PCa drug
Prostate cancer and suicide
Germline & somatic testing is too infrequent
What treatments work after Pluvicto
Pluvicto flare largely lasts only one treatment
Community providers do poor job treating mCSPC men
Webinar: Radionuclide Diagnostics & Theranostics – Theory and Clinical Practice Meet!
Nuclear payloads, guided missiles, directed assassinations…not in global conflict or wars, but prostate cancer and what happens inside bodies of men getting radionuclide theranostics (treatment) and diagnostics (scanning) today.
Radionuclide treatment for prostate cancer is at least 10 years old – does that surprise you? Bayer’s Xofigo was approved in 2013 but adoption has been slow until recent FDA approvals of theranostics (treatment) viz. Pluvicto, and diagnostics (scans) like Illucix and Posluma.
Radionuclides are theory-intense with nuclear medicine doctors less exposed to treatment of advanced prostate cancer. Conversely, GU medical oncologists are less familiar with radionuclides than hormone and chemo-therapy.
Two global experts, GU medical oncologist Dr. Oliver Sartor and nuclear medicine guru, Dr. Philip Kuo will introduce radionuclide theranostics and diagnostics and discuss how the clinic and the theory intersect.
Learn about radionuclide medicine – how it works and what it can do for you! This information will help patients learn how to make sure your Genitourinary Medical Oncologist and Nuclear Medicine Doctor work in harmony.
Watch here:
Special thanks to our sponsors who made this webinar possible….
This could be scary…It’s almost open enrollment season for Medicare!
A dreaded time to receive multiple communications in untold ways that often read like a foreign language. It’s only fitting that we talked about it the day before Halloween.
Join AnCan as we bring experts Amanda Goodstadt, Esq. from Triage Cancer, and Medicare Insurance Broker Kim Umphres to explain all things confusing around 2024 Medicare insurance options, and make this enrollment season a little less spooky and intimidating.
Our panel will explain the whole menu from alphabet soup plans to doughnut holes! Learn the difference between Traditional and Advantage plans and if you can switch between them, what HMOs and PPOs mean, how to sign up to see any doctor anywhere and much more.
Click here for a special handout from Triage Cancer with Medicare resources.
Special thanks to Bayer, Pfizer, Myovant Sciences, Foundation Medicine, Myriad Genetics, Janssen – Johnson & Johnson, Telix, and Blue Earth Diagnostics for sponsoring this webinar.
To SIGN UP for any of our Virtual Support groups, visit our Contact Us page.
There’s no magic bullet in this prostate cancer game… not even focal therapies, good as they sound.
Listen to world expert Dr. Laurence Klotz speak about what makes a good candidate – and why some come out free of side effects while recurrence may be on the cards for others.
What are the different types of focal therapy and is one better than the other?
Most important for YOU – who’s a good candidate, and who may get suckered by a white shoed urologist??
Join us to find out!
Watch here:
Special thanks to Bayer, Pfizer, Myovant Sciences, Foundation Medicine, Myriad Genetics, Janssen – Johnson & Johnson, Telix, and Blue Earth Diagnostics for sponsoring this webinar.
For information on our peer-led video chat PROSTATE CANCER VIRTUAL SUPPORT GROUPS, click here.
To SIGN UP for any of our Virtual Support groups, visit our Contact Us page.
How bad is my prostate cancer??? We’ve all asked ourselves that! Today there are tests to predict its gravity early in the diagnosis and after surgery.
How do these tests work?
… what’s inside the ‘black box’ that makes it an accurate crystal ball?
… and are all tests born equal?
… the test manufacturers won’t say BUT one doc who will is Dr. Todd Morgan – he’s looked inside all of them.
Dr. Morgan is Chief Urologist at the University of Michigan and leads the MUSIC* program.
He will discuss:
the difference between inherited and somatic testing
who should undergo genomic testing
how tests are able to predict
his upcoming randomized trial comparing the leading genomic tests, Decipher, Prolaris, and Oncotype DX
… and more including your questions
* Michigan Urological Surgery and Improvement Collaborative
Dr. Morgan has served on several national guideline committees, including the American Urological Association’s Advanced Prostate Cancer Guidelines, the National Comprehensive Cancer Network’s Prostate Cancer Early Detection Guidelines, the American Society for Clinical Oncology’s Localized Prostate Cancer Guidelines, and the ASCO Molecular Markers for Prostate Cancer Guidelines.
Watch here:
Special thanks to Bayer, Pfizer, Myovant Sciences, Foundation Medicine, Myriad Genetics, Janssen – Johnson & Johnson, Telix, and Blue Earth Diagnostics for sponsoring this webinar.
For information on our peer-led video chat PROSTATE CANCER VIRTUAL SUPPORT GROUPS, click here.
To SIGN UP for any of our Virtual Support groups, visit our Contact Us page.
